0000950170-24-005186.txt : 20240118 0000950170-24-005186.hdr.sgml : 20240118 20240118075534 ACCESSION NUMBER: 0000950170-24-005186 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240117 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Heart Test Laboratories, Inc. CENTRAL INDEX KEY: 0001468492 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 261344466 STATE OF INCORPORATION: TX FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41422 FILM NUMBER: 24540135 BUSINESS ADDRESS: STREET 1: 550 RESERVE ST, SUITE 360 CITY: SOUTHLAKE STATE: TX ZIP: 76092 BUSINESS PHONE: 682-237-7781 MAIL ADDRESS: STREET 1: 550 RESERVE ST, SUITE 360 CITY: SOUTHLAKE STATE: TX ZIP: 76092 8-K 1 hscs-20240117.htm 8-K 8-K
0001468492false0001468492us-gaap:CommonStockMember2024-01-172024-01-170001468492us-gaap:WarrantMember2024-01-172024-01-1700014684922024-01-172024-01-17

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 17, 2024

 

 

Heart Test Laboratories, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Texas

001-41422

26-1344466

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

550 Reserve Street, Suite 360

 

Southlake, Texas

 

76092

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 682 237-7781

 

n/a

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock

 

HSCS

 

The Nasdaq Stock Market LLC

Warrants

 

HSCSW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On January 17, 2024, Heart Test Laboratories, Inc. (the “Company”) held its 2024 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on the eight proposals described below. The proposals presented at the Annual Meeting are described in detail in the Company’s definitive proxy statement for its 2024 Annual Meeting of Shareholders filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 8, 2023 (the “Proxy Statement”).

Of the Company's 53,886,305 shares of common stock, par value $0.001 per share (the "Common Stock") outstanding, and Series C preferred stock, par value $0.001 per share, on an as converted basis outstanding, and entitled to vote at the Annual Meeting, 29,299,177, or 54.37%, of the outstanding shares, were present either in person or by proxy.

The results for each of the proposals submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal 1: Election of Directors Proposal

The following two Class I nominees will serve for a three-year term expiring on the date of the Company’s 2026 Annual Meeting of Shareholders or until his successor is duly elected or his earlier resignation or removal, and the following two Class II nominees will serve for a three-year term expiring on the date of the Company’s 2027 Annual Meeting of Shareholders or until his successor is duly elected or his earlier resignation or removal. The voting with respect to the election of directors was as follows:

Class I Directors

Nominee

Votes For

Withheld

Broker Non-Votes

Brian Szymczak

22,817,292

437,448

6,044,437

Bruce Bent

22,800,131

454,609

6,044,437

Class II Directors

Nominee

Votes For

Withheld

Broker Non-Votes

Mark Hilz

22,877,208

377,532

6,044,437

David R. Wells

22,814,389

440,351

6,044,437

Proposal 2: ELOC Issuance Proposal

The Company’s shareholders approved the full issuance of shares of the Company’s Common Stock issuable by the Company pursuant to its purchase agreement, dated as of March 10, 2023, with Lincoln Park Capital Fund, LLC (the “ELOC Issuance Proposal”) for purposes of complying with Nasdaq Listing Rule 5635(d), by voting as follows:

For

Against

Abstain

Broker Non-Votes

22,113,326

928,881

212,533

6,044,437

Proposal 3: Proposal to Approve the Company’s 2023 Employee Stock Purchase Plan, as Amended

The Company’s shareholders approved the Company’s 2023 Equity Incentive Plan, as amended, by voting as follows:

For

Against

Abstain

Broker Non-Votes

16,969,611

5,682,886

602,244

6,044,437

Proposal 4: Auditor Ratification Proposal

 

The Company’s shareholders ratified the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024 by voting as follows:

For

Against

Abstain

28,840,623

207,972

250,581

Proposal 5: Reverse Stock Split Proposal

 

 

The Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Formation (the “Certificate of Formation”) to effect, at the sole discretion of the Company’s Board of Directors, a reverse stock split of all outstanding shares of the Company’s Common Stock, at a ratio to be determined by the Company’s Board of Directors in the range of one-for-two (1-for-2) through one-for-one hundred (1-for-100), by voting as follows:

For

Against

Abstain

27,379,571

1,761,895

157,711

Proposal 6: Name Change Proposal

The Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Formation to change the Company’s corporate name from “Heart Test Laboratories, Inc.” to “HeartSciences Inc.” by voting as follows:

For

Against

Abstain

28,852,380

239,552

207,243

Proposal 7: Quorum Reduction Proposal

The Company did not receive sufficient proxies from shareholders to approve an amendment to the Company's Certificate of Formation to decrease the number of shares of the Company’s Common Stock needed to establish a quorum for meetings of the Company’s shareholders. Pursuant to the approval of Proposal 8 (below), the Company adjourned the Annual Meeting with respect to Proposal 7. During the period of the adjournment, the Company will continue to solicit votes from its shareholders with respect to Proposal 7. The voting at the time of the Annual Meeting was as follows:

For

Against

Abstain

Broker Non-Votes

26,500,809

1,415,185

367,263

1,015,920

Proposal 8: Adjournment Proposal

The Company’s shareholders approved the one or more adjournments of the Annual Meeting to a later date or dates to solicit additional proxies if there are insufficient votes to approve any of the proposals at the time of the Annual Meeting by voting as follows:

For

Against

Abstain

28,078,902

759,077

461,197

The Company’s shareholders will be able to attend the reconvened Annual Meeting virtually via live webcast at https://web.lumiagm.com/293046675 on Thursday, February 15, 2024 at 9:00 a.m. Eastern Time. The record date for the Annual Meeting remains the close of business on November 20, 2023. The Company shareholders who have already voted do not need to recast their votes unless they wish to change their votes on Proposal 7. The Company’s shareholders of record who have not already voted or wish to change their vote on the Proposal 7 may do so by following the instructions provided in the voting instruction form or proxy card accompanying the Proxy Statement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit No.

Description

99.1

Press Release dated January 18, 2024.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

Additional Information and Where to Find It

This Current Report on Form 8-K may be deemed solicitation material in respect of the Annual Meeting. This communication does not constitute a solicitation of any vote or approval. In connection with the Annual Meeting, the Company has filed with the SEC and has mailed or otherwise provided to its stockholders a proxy statement regarding the business to be conducted at the Annual Meeting. The Company may also file other documents with the SEC regarding the business to be conducted at the Annual Meeting. This document is not a substitute for the proxy statement or any other document that may be filed by the Company with the SEC.

 

 

BEFORE MAKING ANY VOTING DECISION, THE COMPANY’S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY THE COMPANY WITH THE SEC IN CONNECTION WITH THE BUSINESS TO BE CONDUCTED AT THE ANNUAL MEETING BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE BUSINESS TO BE CONDUCTED AT THE ANNUAL MEETING BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS TO BE CONDUCTED AT THE ANNUAL MEETING.

The Company’s stockholders may obtain a free copy of the proxy statement and other documents the Company files with the SEC (when available) through the website maintained by the SEC at www.sec.gov. The Company makes available free of charge on its investor relations website at ir.heartsciences.com copies of materials it files with, or furnishes to, the SEC.

Participants in the Solicitation

The Company and its directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the business to be conducted at the Annual Meeting. Security holders may obtain information regarding the names, affiliations and interests of the Company’s directors and executive officers in the Proxy Statement. To the extent the holdings of the Company’s securities by the Company’s directors and executive officers have changed since the amounts set forth in the Proxy Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about the Company’s beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the SEC on July 18, 2023, Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2023, filed with the SEC on December 14, 2023, and in the Company’s other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

HEART TEST LABORATORIES, INC.

 

 

 

 

Date:

January 18, 2024

By:

/s/ Andrew Simpson

 

 

Name:

Title:

Andrew Simpson
President, Chief Executive Officer, and Chairman of the Board of Directors
 

 

 

 EX-99.1 2 hscs-ex99_1.htm EX-99.1 EX-99.1

 

 

Exhibit 99.1

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

 

Southlake, TX, January 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) as well as an adjournment of the Annual Meeting as outlined below.

 

At the Annual Meeting which was convened, all items of business were passed, with the exception of Proposal 7, which would effect a reduction of the quorum requirements for future shareholder meetings, as the Company had not received sufficient proxies for approval by the time of the Annual Meeting. Accordingly, the meeting was convened and adjourned solely in respect of proposal 7.

 

Andrew Simpson, CEO, commented, “We are delighted to have received the support of our shareholders to pass a number of important resolutions and thank our shareholders for their participation."

 

Results of Annual Meeting

 

At the Annual Meeting, approximately 54.37% of the Company’s outstanding shares of common stock and Series C Preferred Stock voting together as a single class on an as converted basis, were represented in person or by proxy, representing a quorum.

 

Proposal 1 - the Class I director nominees Brian Szymczak and Bruce Bent, and Class II director nominees Mark Hilz and David R. Wells were re-elected, in each case to the Company’s Board of Directors. Each director nominee received a plurality of votes cast at the Annual Meeting.

 

Proposal 2 – the Company’s shareholders approved the full issuance of shares of common stock issuable by the Company pursuant to its Equity Line of Credit for purposes of complying with Nasdaq Listing Rule 5635(d).

 

Proposal 3 – the Company’s shareholders approved the Company‘s 2023 Equity Incentive Plan, as amended.

 

Proposal 4 –the Company’s shareholders ratified Haskell & White LLP as the Company’s independent registered public accounting firm for the year ending April 30, 2024.

 

Proposal 5 – the Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Formation to effect, at the sole discretion of the Board of Directors, a reverse stock split of all outstanding shares of the Company’s common stock, in the range of one-for-two (1-for-2) through one-for-one hundred (1-for-100), as determined by the Board of Directors.

 

Proposal 6 – the Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Formation to change the Company’s corporate name from “Heart Test Laboratories, Inc” to “HeartSciences”.

 

Proposal 8 - the Company’s shareholders approved one or more adjournments of the Annual Meeting to a later date or dates to solicit additional proxies if there are insufficient votes to approve any of the proposals at the time of the Annual Meeting.

 

Adjournment of Meeting

 

With respect to Proposal 7, an amendment to the Company’s Amended and Restated Certificate of Formation to lower the quorum for future meetings to one-third of the shares eligible to vote, - as of the Annual Meeting date, approximately 49% of the shares eligible to vote had been voted in favor of the proposal. As a result, the Company adjourned the Annual Meeting solely with respect to this proposal until Thursday, February 15, 2024 in order to solicit additional votes.

 

The Annual Meeting, with respect to Proposal 7, will reconvene on Thursday, February 15, 2024 at 9:00 a.m. eastern time. The reconvened Annual Meeting will be held virtually via a live webcast at https://web.lumiagm.com/29304667. Shareholders who have already submitted their proxy do not need to resubmit their proxy. Proxies previously submitted in respect to Proposal 7 will be voted at the reconvened Annual Meeting, unless properly revoked in accordance with the procedures described in the Proxy Statement. The record date for determining shareholders eligible to vote at the reconvened Annual Meeting will remain at the close of business on November 20, 2023.

 

The Company strongly encourages all shareholders of record as of November 20, 2023, who have not yet voted for Proposal 7, to do so by February 14, 2024 at 11:59 p.m. Eastern Time. Shareholders who have any questions are require assistance with completing a proxy or voting instruction form or who do not have the required materials, may contact Advantage Proxy, Inc. toll-free at 1-877-870-8565 or by e-mail at ksmith@advantageproxy.com.

 

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Undetected heart disease is one of the biggest challenges in healthcare and millions of ECGs are performed every week. The Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. HeartSciences also has an industry leading library of AI-ECG algorithms, technologies and patent rights developed using millions of ECG records which the Company intends to deliver using a cloud-based, hardware agnostic platform to accept ECGs from millions of existing ECG devices around the world, in addition to the MyoVista®.

For more information, please visit: https://www.heartsciences.com. Twitter: @HeartSciences

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating

performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2023, filed with the SEC on September 14, 2023, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

 

Contacts:

HeartSciences
Gene Gephart
+1-682-244-2578 Ext. 2024 (US)
info@heartsciences.com 

 

Investors
Gilmartin Group
Vivian Cervantes
investorrelations@heartsciences.com 

 

 EX-101.SCH 3 hscs-20240117.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Document Information Document Information [Table] Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Class of Stock [Domain] CIK Entity Central Index Key Entity Tax Identification Number Registrant Name Entity Registrant Name Class of Stock [Axis] Entity Ex Transition Period Entity Information, Former Legal or Registered Name Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Document Information: Document Information [Line Items] Warrant [Member] Common Stock [Member] Pre-commencement Tender Offer Cover Cover [Abstract] Security Exchange Name Entity Emerging Growth Company Amendment Amendment Flag Entity File Number Entity Address, Address Line One Title of 12(b) Security Document Type Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information
Jan. 17, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 17, 2024
Entity Registrant Name Heart Test Laboratories, Inc.
Entity Central Index Key 0001468492
Entity Emerging Growth Company true
Entity File Number 001-41422
Entity Incorporation, State or Country Code TX
Entity Tax Identification Number 26-1344466
Entity Address, Address Line One 550 Reserve Street, Suite 360
Entity Address, City or Town Southlake
Entity Address, State or Province TX
Entity Address, Postal Zip Code 76092
City Area Code 682
Local Phone Number 237-7781
Entity Information, Former Legal or Registered Name n/a
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock
Trading Symbol HSCS
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants
Trading Symbol HSCSW
Security Exchange Name NASDAQ
XML 5 hscs-20240117_htm.xml IDEA: XBRL DOCUMENT 0001468492 us-gaap:CommonStockMember 2024-01-17 2024-01-17 0001468492 us-gaap:WarrantMember 2024-01-17 2024-01-17 0001468492 2024-01-17 2024-01-17 0001468492 false 8-K 2024-01-17 Heart Test Laboratories, Inc. TX 001-41422 26-1344466 550 Reserve Street, Suite 360 Southlake TX 76092 682 237-7781 n/a false false false false Common Stock HSCS NASDAQ Warrants HSCSW NASDAQ true false EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports hscs-20240117.htm hscs-20240117.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hscs-20240117.htm": { "nsprefix": "hscs", "nsuri": "http://heartsciences.com/20240117", "dts": { "inline": { "local": [ "hscs-20240117.htm" ] }, "schema": { "local": [ "hscs-20240117.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_b36e3de3-999a-4c1a-981e-3794fe65b8de", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "hscs-20240117.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b36e3de3-999a-4c1a-981e-3794fe65b8de", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "hscs-20240117.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information:", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "CIK", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://heartsciences.com/20240117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 12 0000950170-24-005186-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-005186-xbrl.zip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end